Impact BioMedical Inc. (IBO): Technical Path Toward $5.50
Key Takeaways
- The $5.50 objective is not an analyst price target; IBO has no published sell-side coverage, so the figure reflects a technical mean-reversion level near the stock's 50-day moving average of roughly $5.71.
- At the latest verified close of $3.98, reaching $5.50 would require a gain of roughly 38%.
- The stock trades within a 52-week range of $3.84 to $10.47 and has fallen about 49% over the past year, including after a 1-for-12.62 reverse split in September 2026.
- Financials are extremely thin: trailing-twelve-month revenue is only about $35,000 against net losses of roughly $11.9 million.
- The strongest support for a rebound is an oversold reading (RSI near 29) and a diversified early-stage pipeline of health and wellness technologies.
- The biggest risks are negligible revenue, ongoing losses, a weak cash position, a tiny float, and elevated volatility (beta of 2.73).
Setting the $5.50 Technical Benchmark
Impact BioMedical is not followed by any verifiable sell-side analysts, so there is no credible analyst consensus, no average analyst price target, and no meaningful target range to calculate. Rather than invent a consensus, the $5.50 figure used here is drawn from public technical discussion: it sits just below the stock's 50-day moving average of about $5.71 and within the lower portion of the range where shares consolidated immediately after the September 2026 reverse split. It is a realistic technical milestone, not a fundamental valuation, and it should not be read as a forecast. I also checked this using Tickeron’s AI Pattern Search Engine to see how the levels compare historically.
Where the Stock Stands Today and the Road Ahead
Shares last closed at $3.98, near the bottom of the 52-week range of $3.84 to $10.47. The required move to $5.50 is roughly 38%, which is a very large gain for any equity and especially for a thinly traded micro-cap. The stock has declined about 35% over the past month and about 34% over three months, meaning a recovery toward $5.50 would represent only a partial retracement of recent losses, not a return to prior highs.
Reaching the objective would likely require a meaningful stabilization first, followed by renewed buying interest in an extremely illiquid market. With a float of roughly 910,000 shares, order flow—not fundamental news—can drive outsized price swings in either direction.
Factors That Could Aid a Rebound
The most concrete support is technical: the Relative Strength Index (RSI, a momentum gauge) has fallen to about 29, a level often associated with oversold conditions that can precede short-term bounces. Any positive company news could also help. Impact BioMedical is advancing several early-stage assets, including its Linebacker polyphenol platform for oncology, inflammatory, and neurological applications; its Laetose technology; and its Equivir and Equivir G antiviral polyphenol formulations, alongside functional fragrance products. A partnership, licensing deal, or funding announcement—particularly from its parent, DSS BioHealth Security, Inc.—could refocus attention on the company and lift sentiment.
Key Risks to Consider
The fundamental picture is challenging. Trailing-twelve-month revenue of roughly $35,000 means the company is effectively pre-revenue, while net losses run near $11.9 million annually. The balance sheet is strained, with a current ratio of about 0.16 and only about $10,000 in cash as of the most recent quarter, leaving limited runway without additional financing. The recent 1-for-12.62 reverse split was designed to maintain exchange listing compliance and signals financial pressure. High volatility, a beta near 2.73, and an absence of analyst or institutional sponsorship mean there is no valuation floor beneath the shares, and further dilution through equity raises remains a persistent risk.
Chart Levels Worth Watching
The 52-week low of $3.84 is the immediate support level; a decisive break below it would leave the stock in uncharted territory. The 50-day moving average near $5.71 and the 200-day moving average near $6.44 are the main resistance levels overhead. The $5.00 mark is a psychological round-number level, while the post-split consolidation zone between roughly $5.40 and $7.50 represents a broader band of overhead supply. Because trading volume is extremely low—often under 15,000 shares per day—these levels can be breached quickly but are also prone to sharp reversals.
What to Keep an Eye On Going Forward
Because the $5.50 objective is technical rather than analyst-derived, there is no published 12-month research horizon attached to it. Investors should watch for the company's next earnings filing, any announcements of financing, licensing, or product milestones, and whether the stock can hold above the $3.84 support level. Changes in the reverse-split-adjusted share count and any sign of institutional or insider buying would also be relevant, as would broad risk appetite toward speculative biotechnology names. From what I see, monitoring these elements closely helps frame the setup more clearly.
Using Tickeron’s AI Daily Buy/Sell Signals in My Process
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a thinly traded name like IBO, these signals can help traders spot changing trends, monitor positions, and identify opportunities more efficiently than manual chart review. I find them useful as a complement when reviewing names with limited coverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for IBO turns negative, indicating new downward trend
IBO saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned negative. In 38 of the 39 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IBO turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In 11 of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
IBO moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
IBO broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IBO entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 67 of 85 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.452) is normal, around the industry mean (26.782). P/E Ratio (0.505) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. IBO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement